Prognosis in primary effusion lymphoma is associated with the number of body cavities involved

Leukemia and Lymphoma

Volumn 53, Issue 12, 2012, Pages 2378-2382

  Castillo, Jorge J ^a   Shum, Helen ^a   Lahijani, Majid ^a   Winer, Eric S ^a   Butera, James N ^a  

^a RHODE ISLAND HOSPITAL   (United States)

Author keywords

HHV8; KSHV; PEL; Primary effusion lymphoma; Prognosis; Prognostic factors

Indexed keywords

CD20 ANTIGEN; CD30 ANTIGEN; CIDOFOVIR; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; INTERFERON; PREDNISONE; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN HERPESVIRUS 8; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD20; ANTIGENS, CD30; FEMALE; HERPESVIRUS 8, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, PRIMARY EFFUSION; MALE; MIDDLE AGED; PERICARDIUM; PERITONEAL CAVITY; PLEURAL CAVITY; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; REVIEW LITERATURE AS TOPIC; SEX FACTORS;

EID: 84868342580     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.694075     Document Type: Article

References (31)

1. Cesarman E, Chang Y, Moore PS, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995;332:1186-1191.
2. Chen YB, Rahemtullah A, Hochberg E. Primary effusion lymphoma. Oncologist 2007;12:569-576. (Pubitemid 350012120)
3. Cesarman E, Nador RG, Aozasa K, et al. Kaposi's sarcomaassociated herpesvirus in non-AIDS related lymphomas occurring in body cavities. Am J Pathol 1996;149:53-57. (Pubitemid 26230978)
4. Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996;88:645-656. (Pubitemid 26240396)
5. Said J, Cesarman E. Primary effusion lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 260-261.
6. Boulanger E, Afonso PV, Yahiaoui Y, et al. Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin. Am J Transplant 2008;8:707-710. (Pubitemid 351287542)
7. De Filippi R, Iaccarino G, Frigeri F, et al. Elevation of clonal serum free light chains in patients with HIV-negative primary effusion lymphoma (PEL) and PEL-like lymphoma. Br J Haematol 2009;147: 405-408.
8. Humphrey RW, Davis DA, Newcomb FM, et al. Human herpesvirus 8 (HHV-8) in the pathogenesis of Kaposi's sarcoma and other diseases. Leuk Lymphoma 1998;28:255-264. (Pubitemid 28105032)
9. Said J. Kaposi's sarcoma-associated herpesvirus (KSHV): a new viral pathogen associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. West J Med 1997;167: 37-38. (Pubitemid 27328347)
10. Ballestas ME, Chatis PA, Kaye KM. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 1999;284:641-644. (Pubitemid 29289588)
11. Sakakibara S, Ueda K, Nishimura K, et al. Accumulation of heterochromatin components on the terminal repeat sequence of Kaposi's sarcoma-associated herpesvirus mediated by the latencyassociated nuclear antigen. J Virol 2004;78:7299-7310. (Pubitemid 38915876)
12. Friborg J Jr, Kong W, Hottiger MO, et al. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999;402: 889-894.
13. Radkov SA, Kellam P, BoshoffC. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 2000;6:1121-1127.
14. Fujimuro M, Wu FY, ApRhys C, et al. A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat Med 2003;9:300-306. (Pubitemid 36362785)
15. Rivas C, Thlick AE, Parravicini C, et al. Kaposi' s sarcomaassociated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol 2001;75:429-438.
16. Asou H, Said JW, Yang R, et al. Mechanisms of growth control of Kaposi's sarcoma-associated herpes virus-associated primary effusion lymphoma cells. Blood 1998;91:2475-2481. (Pubitemid 28155523)
17. Sakakibara S, Tosato G. Viral interleukin-6: role in Kaposi' s sarcoma-associated herpesvirus: associated malignancies. J Interferon Cytokine Res 2011;31:791-801.
18. Cesarman E, Mesri EA. Kaposi sarcoma-associated herpesvirus and other viruses in human lymphomagenesis. Curr Top Microbiol Immunol 2007;312:263-287. (Pubitemid 47400340)
19. Dittmer DP, Krown SE. Targeted therapy for Kaposi' s sarcoma and Kaposi's sarcoma-associated herpesvirus. Curr Opin Oncol 2007;19:452-457. (Pubitemid 47356601)
20. Boulanger E, Gerard L, Gabarre J, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 2005;23:4372-4380. (Pubitemid 46207011)
21. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586. (Pubitemid 350002966)
22. Kobayashi Y, Kamitsuji Y, Kuroda J, et al. Comparison of human herpes virus 8 related primary effusion lymphoma with human herpes virus 8 unrelated primary effusion lymphoma-like lymphoma on the basis of HIV: report of 2 cases and review of 212 cases in the literature. Acta Haematol 2007;117:132-144. (Pubitemid 46496796)
23. Matsumoto Y, Nomura K, Ueda K, et al. Human herpesvirus 8-negative malignant effusion lymphoma: a distinct clinical entity and successful treatment with rituximab. Leuk Lymphoma 2005;46:415-419. (Pubitemid 40220399)
24. Perez CL, Rudoy S. Anti-CD20 monoclonal antibody treatment of human herpesvirus 8-associated, body cavity-based lymphoma with an unusual phenotype in a human immunodeficiency virus-negative patient. Clin Diagn Lab Immunol 2001;8:993-996. (Pubitemid 32868320)
25. Siddiqi T, Joyce RM. A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab. Clin Lymphoma Myeloma 2008;8:300-304.
26. Bhatt S, Ashlock B, Natkunam Y, et al. Preclinical activity of brentuximab vedotin (SGN-35) in primary effusion lymphoma (PEL). Blood 2011;118(Suppl. 1): Abstract 3728.
27. Sarosiek KA, Cavallin LE, Bhatt S, et al. Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. Proc Natl Acad Sci USA 2010;107:13069-13074.
28. Matta H, Chaudhary PM. The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. Cancer Biol Ther 2005;4:77-82. (Pubitemid 41350935)
29. An J, Sun Y, Fisher M, et al. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 2004;18: 1699-1704. (Pubitemid 39386350)
30. Waddington TW, Aboulafia DM. Failure to eradicate AIDSassociated primary effusion lymphoma with high-dose chemotherapy and autologous stem cell reinfusion: case report and literature review. AIDS Patient Care STDS 2004;18:67-73. (Pubitemid 38240871)
31. Won JH, Han SH, Bae SB, et al. Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus. Int J Hematol 2006;83:328-330.